维昇药业-B：注射用隆培生长激素的生物制品上市许可申请获国家药监局批准

Core Viewpoint - The approval of the long-acting growth hormone, Lonapegsomatropin (SKYTROFA), by the National Medical Products Administration of China marks a significant advancement in the treatment of pediatric growth hormone deficiency (PGHD) in children aged 3 years and older [1][2]. Group 1: Product Overview - Lonapegsomatropin is a weekly administered growth hormone replacement therapy for children with PGHD, demonstrating superior efficacy and equivalent safety compared to daily injections of short-acting growth hormone [2][3]. - The drug features a novel molecular design that allows for sustained release of unmodified human growth hormone, matching the structure and mechanism of endogenous growth hormone produced by the pituitary gland [2]. Group 2: Clinical Trial Results - The pivotal Phase 3 trial for Lonapegsomatropin involved children aged 3 to 17 years, showing an annualized height velocity of 10.66 cm/year compared to 9.75 cm/year for the short-acting group, with a statistically significant difference of 0.91 cm/year (95% CI: 0.37-1.45, P=0.0010) [3]. - At 52 weeks, the height standard deviation score (SDS) increased by 1.01 in the Lonapegsomatropin group versus 0.83 in the short-acting group, with a p-value of 0.0015, indicating significant improvement from week 13 onwards [3]. Group 3: Commercialization Strategy - Following the BLA approval, the company has initiated a comprehensive commercialization plan to ensure supply and expand market coverage, including a supply agreement with Ascendis Pharma [4]. - The company is enhancing its commercialization capabilities through a dedicated team and tailored strategies for market access and physician awareness, alongside strategic partnerships with companies like Shanghai Pharmaceuticals, United Family Healthcare, and Anke Bio [4].